Evidence map›Paper›PMID 42201662›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Epitope-Resolved Digital SERS Profiling of Structurally Dynamic Antigens via a Multi-Epitope Bispecific Antibody Framework.

Jing Wang, Quan Zhou, Kym Lowry, Christopher B Howard, Matt Trau

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jing WangKey Laboratory of OptoElectronic Science and Technology for Medicine of Ministry of Education, Fujian Provincial Key Laboratory of Photonics Technology, Fujian Normal University, Fuzhou, China.
Quan ZhouAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD, Australia.
Kym LowryFrazer Institute, Faculty of Health, Medicine, and Behavioural Sciences, The University of Queensland, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
Christopher B HowardAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD, Australia.
Matt TrauAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD, Australia.

Funding

Advance Queensland Fellowship AQIRF104-2020-CVAustralian Research Council FL220100059Cancer Australia 2010799Guiding Projects of Fujian Province 2023Y0058Joint Funds for the Innovation of Science and Technology, Fujian Province 2021Y9228National Health and Medical Research Council APP1185907National Health and Medical Research Council APP2039176Science Fund Program for Excellent Young Scientists of Fujian 2024J09030
6 · The paper itself

Abstract

Digital surface-enhanced Raman scattering (SERS) immunoassays digitize epitope binding events to achieve ultrasensitive protein detection. However, existing implementations predominantly rely on single-epitope recognition, yielding 1D molecular view of antigen structure and obscuring how conformational heterogeneity or mutation-induced changes affect epitopes. This limitation cannot be resolved simply by combining multiple monoclonal antibodies, as heterogeneous conjugation and uncontrolled binding collapse epitope-specific responses into pooled, non-assignable signals. Here, we introduce EpiCount-SERS (Epitope-Resolved Digital Counting by SERS), a multi-epitope digital SERS framework that enables epitope-resolved immunochemical profiling. The platform employs nanobody-based bispecific antibody fragments that pair epitope-specific nanobodies with a unified anti-methoxy polyethylene glycol conjugation domain, enabling orientation-controlled attachment to spectrally encoded SERS nanotags. Epitope-specific binding events are discretized into independent digital channels, allowing distinct epitopes on the SARS-CoV-2 receptor-binding domain to be interrogated in parallel. Digital enumeration across these channels generates epitope-resolved molecular fingerprints that capture information beyond single-epitope assays. EpiCount-SERS achieves sub-ng mL

Indexed as

Antibodies, BispecificEpitopesSARS-CoV-2Spectrum Analysis, RamanHumansImmunoassayAntibodies, BispecificEpitopesbispecific antibody fragmentsepitope‐resolved sensingmulti‐epitope immunoprofilingmutation‐sensitive antigen detectionviral protein variants

Identifiers

PMID42201662
PMCPMC13336131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.